Log in

NASDAQ:AMAG - AMAG Pharmaceuticals Stock Price, Forecast & News

+0.21 (+2.79 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
Now: $7.75
50-Day Range
MA: $9.79
52-Week Range
Now: $7.75
Volume1.04 million shs
Average Volume520,468 shs
Market Capitalization$262.80 million
P/E RatioN/A
Dividend YieldN/A
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AMAG



Sales & Book Value

Annual Sales$474 million
Cash Flow$1.62 per share
Book Value$21.62 per share


Net Income$-65,760,000.00


Market Cap$262.80 million
Next Earnings Date3/5/2020 (Estimated)

Receive AMAG News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter.

AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) released its quarterly earnings data on Friday, November, 1st. The specialty pharmaceutical company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.19. The specialty pharmaceutical company earned $84.13 million during the quarter, compared to analyst estimates of $88.25 million. AMAG Pharmaceuticals had a negative return on equity of 34.59% and a negative net margin of 88.54%. The business's revenue for the quarter was down 31.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.89 EPS. View AMAG Pharmaceuticals' Earnings History.

When is AMAG Pharmaceuticals' next earnings date?

AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for AMAG Pharmaceuticals.

What guidance has AMAG Pharmaceuticals issued on next quarter's earnings?

AMAG Pharmaceuticals issued an update on its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $324-329 million, compared to the consensus revenue estimate of $327.37 million.

What price target have analysts set for AMAG?

7 analysts have issued 1-year price targets for AMAG Pharmaceuticals' shares. Their forecasts range from $6.00 to $16.00. On average, they expect AMAG Pharmaceuticals' share price to reach $12.67 in the next year. This suggests a possible upside of 63.4% from the stock's current price. View Analyst Price Targets for AMAG Pharmaceuticals.

What is the consensus analysts' recommendation for AMAG Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMAG Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AMAG Pharmaceuticals.

What are Wall Street analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "Our $16 price target for AMAG is based on our sum-of-the-parts NPV valuation based on each of the company’s assets; we value the company’s commercail assets, and pipeline assets, ciraparantag ($9.07) and AMG-423 ($1.75) and deduct unallocated R&D and corporate expenses ($10.78). We have negligible value for Intrarosa and MuGard. Our valuation model utilizes a discount rate of 10.4% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%). We adjust each pipeline indication for probability of success with ciraparantag at 50% (adjusting for risk of ultimate approval as well as probability of establishing differentiated profile); and AMAG-423 at 33%." (8/8/2019)
  • 2. According to Zacks Investment Research, "AMAG reported wider than expected loss and sales missed estimates in the first quarter of 2019. The company’s drug-Makena’s generic hit the market in July 2018, which pulled down the drug’s sales. Feraheme currently competes with IV iron replacement therapies like Venofer, Injectafer, Ferrlecit and their generic versions, among others. Shares of the company have underperformed the industry year to date.  However, the FDA approved the label expansions of Feraheme and Makena, and accepted  the NDA for Vyleesi with an action date of June 23, 2019 bodes well for the company. Meanwhile,the company broadened its product pipeline by adding two promising development-stage assets — AMAG-423, an orphan drug for the potential treatment of severe preeclampsia and thein-licensing of Intrarosa. The company also divested the Cord Blood Registry (CBR) business and strengthened its balance sheet." (6/20/2019)
  • 3. Cantor Fitzgerald analysts commented, ": We reiterate our Neutral rating and are lowering our PT to $14 from $17. Failure of the post-approval Makena trial is a clear setback for the company. We suspect investors may be increasingly drawn to the stock as one to own given the subsequent devaluation, but that longer-term investing requires some framing of the commercial impact. We believe the trial result reinforces the importance of the next 12-18 months for AMAG to demonstrate that existing and pipeline assets can adequately replace lost Makena revenue." (3/14/2019)

Has AMAG Pharmaceuticals been receiving favorable news coverage?

Media headlines about AMAG stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AMAG Pharmaceuticals earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for AMAG Pharmaceuticals.

Are investors shorting AMAG Pharmaceuticals?

AMAG Pharmaceuticals saw a drop in short interest in the month of February. As of February 14th, there was short interest totalling 13,790,000 shares, a drop of 5.8% from the January 30th total of 14,640,000 shares. Based on an average trading volume of 721,200 shares, the days-to-cover ratio is currently 19.1 days. Approximately 47.3% of the shares of the stock are sold short. View AMAG Pharmaceuticals' Current Options Chain.

Who are some of AMAG Pharmaceuticals' key competitors?

What other stocks do shareholders of AMAG Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AMAG Pharmaceuticals investors own include Celgene (CELG), Bausch Health Companies (BHC), Palatin Technologies (PTN), Gilead Sciences (GILD), Broadcom (AVGO), Energy Transfer LP Unit (ET), Netflix (NFLX), NVIDIA (NVDA), Skyworks Solutions (SWKS) and Ford Motor (F).

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the folowing people:
  • Dr. William K. Heiden, CEO, Pres & Director (Age 59)
  • Mr. Edward H. Myles, Exec. VP, CFO & Treasurer (Age 47)
  • Mr. Joseph D. Vittiglio, Exec. VP of Legal Affairs and Quality, Gen. Counsel & Corp. Sec. (Age 47)
  • Dr. Julie Krop, Exec. VP of Devel. & Chief Medical Officer (Age 53)
  • Ms. Linda S. Lennox, VP of Investor Relations & Corp. Communications

Who are AMAG Pharmaceuticals' major shareholders?

AMAG Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LP (8.98%), State Street Corp (8.00%), Renaissance Technologies LLC (5.99%), Jacobs Levy Equity Management Inc. (2.15%), Connor Clark & Lunn Investment Management Ltd. (2.01%) and Geode Capital Management LLC (1.40%). Company insiders that own AMAG Pharmaceuticals stock include Armistice Capital Master Fund, Armistice Capital, Llc, Camber Capital Management Lp, Elizabeth Scott Bolgiano, Joseph Vittiglio, Julie Krop and William K Heiden. View Institutional Ownership Trends for AMAG Pharmaceuticals.

Which major investors are selling AMAG Pharmaceuticals stock?

AMAG stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Acadian Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., Royce & Associates LP, Panagora Asset Management Inc., Prudential Financial Inc., Rafferty Asset Management LLC and Spark Investment Management LLC. View Insider Buying and Selling for AMAG Pharmaceuticals.

Which major investors are buying AMAG Pharmaceuticals stock?

AMAG stock was bought by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., State Street Corp, KBC Group NV, Oxford Asset Management LLP, Russell Investments Group Ltd., Permanens Capital L.P., Great West Life Assurance Co. Can and Jane Street Group LLC. Company insiders that have bought AMAG Pharmaceuticals stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc, Camber Capital Management Lp, Elizabeth Scott Bolgiano, Julie Krop and William K Heiden. View Insider Buying and Selling for AMAG Pharmaceuticals.

How do I buy shares of AMAG Pharmaceuticals?

Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG stock can currently be purchased for approximately $7.75.

How big of a company is AMAG Pharmaceuticals?

AMAG Pharmaceuticals has a market capitalization of $262.80 million and generates $474 million in revenue each year. The specialty pharmaceutical company earns $-65,760,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis. AMAG Pharmaceuticals employs 467 workers across the globe.View Additional Information About AMAG Pharmaceuticals.

What is AMAG Pharmaceuticals' official website?

The official website for AMAG Pharmaceuticals is http://www.amagpharma.com/.

How can I contact AMAG Pharmaceuticals?

AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]

MarketBeat Community Rating for AMAG Pharmaceuticals (NASDAQ AMAG)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  405 (Vote Outperform)
Underperform Votes:  519 (Vote Underperform)
Total Votes:  924
MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMAG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMAG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel